Aaby, P., Bukh, J., Leerhoy, J., Lisse, I. M., Mordhorst, C. H. & Pedersen, I. R. (1986). Vaccinated Children Get Milder Measles Infection: A Community Study from Guinea-Bissau. Journal of Infectious Diseases, 154(5), 858–863. doi.org/10.1093/infdis/154.5.858
ACA Müller ADAG Pharma AG. (2009, Oktober). Fachinformation Priorix. dimdi. https://portal.dimdi.de/amispb/doc/pei/Web/2603289-spcde-20091001.pdf
Ackley, S. F., Hacker, J. K., Enanoria, W. T. A., Worden, L., Blumberg, S., Porco, T. C. & Zipprich, J. (2018). Genotype-Specific Measles Transmissibility: A Branching Process Analysis. Clinical Infectious Diseases, 66(8), 1270–1275. doi.org/10.1093/cid/cix974
Aoki, Y., Mizuta, K., Ikeda, T., Abiko, C., Itagaki, T. & Ahiko, T. (2013). Isolation of Vaccine-Derived Measles Viruses from Children with Acute Respiratory Infection. The Tohoku Journal of Experimental Medicine, 230(2), 111–115. https://doi.org/10.1620/tjem.230.111
Apotheken Umschau. (2018, 6. Februar). Braucht Deutschland eine Impfpflicht? Abgerufen am 9. August 2022, von https://web.archive.org/web/20180711000720/https://www.apotheken-umschau.de/Infektion/Braucht-Deutschland-eine-Impfpflicht-548597.html
arznei-telegramm. (2013). DISKUSSION UM DIE MASERNIMPFUNG. arznei-telegramm, 44, 85–87. Abgerufen von https://www.arznei-telegramm.de/html/2013_10/1310085_01.html
ASSET. o. J. Compulsory Vaccination and Rates of Coverage Immunisation in Europe. Abruf 14.02.2019
Augusto, G. F., Cruz, D., Silva, A., Pereira, N., Aguiar, B., Leça, A., . . . Freitas, G. (2018). Challenging measles case definition: three measles outbreaks in three Health Regions of Portugal, February to April 2018. Eurosurveillance, 23(28), pii=1800328. doi.org/10.2807/1560-7917.es.2018.23.28.1800328
Avramovich, E., Indenbaum, V., Haber, M., Amitai, Z., Tsifanski, E., Farjun, S., . . . Galor, I. (2018). Measles Outbreak in a Highly Vaccinated Population — Israel, July–August 2017. MMWR. Morbidity and Mortality Weekly Report, 67(42), 1186–1188. doi.org/10.15585/mmwr.mm6742a4
Bankamp, B., Takeda, M., Zhang, Y., Xu, W. & Rota, P. A. (2011). Genetic Characterization of Measles Vaccine Strains. The Journal of Infectious Diseases, 204(suppl_1), S533–S548. https://doi.org/10.1093/infdis/jir097
Barkin, R. M. (1975). Measles mortality: a retrospective look at the vaccine era. American Journal of Epidemiology, 102(4), 341–349. doi.org/10.1093/oxfordjournals.aje.a112170
Barrett, P., Chaintarli, K., Ryan, F., Cotter, S., Cronin, A., Carlton, L., . . . Migone, C. (2016). An ongoing measles outbreak linked to a suspected imported case, Ireland, April to June 2016. Eurosurveillance, 21(27). https://doi.org/10.2807/1560-7917.es.2016.21.27.30277
Beier, D. (2017, Januar). SIKO aktualisiert Impfempfehlungen bei Masern-Mumps-Röteln, Influenza, Hepatitis B und HPV. Abgerufen am 14. Juli 2022, von www.kvs-sachsen.de/fileadmin/data/kvs/img/Mitglieder/KVS-Mitteilungen/2017-02/2017-02_schutzimpfungen.pdf
Bellini, W. & Rota, P. A. (1998). Genetic Diversity of Wild-Type Measles Viruses: Implications for Global Measles Elimination Programs. Emerging Infectious Diseases, 4(1), 29–35. doi.org/10.3201/eid0401.980105
Bennett, J. V., Cutts, F. T. & Katz, S. L. (1999). Edmonston-Zagreb Measles Vaccine: A Good Vaccine With an Image Problem. Pediatrics, 104(5), 1123. https://doi.org/10.1542/peds.104.5.1123
Bernsen, R. M. D., & van der Wouden, J. C. (2008). Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children. Pediatric Allergy and Immunology, 19(6), 544–551. https://doi.org/10.1111/j.1399-3038.2007.00684.x
Betsch, C. & Böhm, R. (2016). Detrimental effects of introducing partial compulsory vaccination: experimental evidence. The European Journal of Public Health, 26(3), 378–381. doi.org/10.1093/eurpub/ckv154
BGH. 1977. BGHSt 6, 90; OLG Frankfurt NJW 1977, 2128.
Bianchi, F. P., Stefanizzi, P., de Nitto, S., Larocca, A. M. V., Germinario, C. & Tafuri, S. (2019). Long-term Immunogenicity of Measles Vaccine: An Italian Retrospective Cohort Study. The Journal of Infectious Diseases, 221(5), 721–728. doi.org/10.1093/infdis/jiz508
Bitnun, A., Shannon, P., Durward, A., Rota, P. A., Bellini, W. J., Graham, C., . . . Tellier, R. (1999). Measles Inclusion‐Body Encephalitis Caused by the Vaccine Strain of Measles Virus. Clinical Infectious Diseases, 29(4), 855–861. https://doi.org/10.1086/520449
Bitzegeio, J., Majowicz, S., Matysiak-Klose, D., Sagebiel, D. & Werber, D. (2019). Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity. Eurosurveillance, 24(17), pii=1800529. doi.org/10.2807/1560-7917.es.2019.24.17.1800529
Bolotin, S., Osman, S., Hughes, S. L., Ariyarajah, A., Tricco, A. C., Khan, S., Li, L., Johnson, C., Friedman, L., Gul, N., Jardine, R., Faulkner, M., Hahné, S. J. M., Heffernan, J. M., Dabbagh, A., Rota, P. A., Severini, A., Jit, M., Durrheim, D. N., … Crowcroft, N. S. (2022). In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis. The Journal of Infectious Diseases, 226(7), 1127–1139. https://doi.org/10.1093/infdis/jiac039
Campbell, H., Andrews, N., Brown, K. E. & Miller, E. (2007). Review of the effect of measles vaccination on the epidemiology of SSPE. International Journal of Epidemiology, 36(6), 1334–1348. https://doi.org/10.1093/ije/dym207
Carazo Perez, S., De Serres, G., Bureau, A. & Skowronski, D. M. (2017). Reduced Antibody Response to Infant Measles Vaccination: Effects Based on Type and Timing of the First Vaccine Dose Persist After the Second Dose. Clinical Infectious Diseases, 65(7), 1094–1102. doi.org/10.1093/cid/cix510
Carson, M. M., Spady, D. W., Albrecht, P., Beeler, J. A., Thipphawong, J., Barreto, L., Grimsrud, K. M., & Pabst, H. F. (1995). Measles vaccination of infants in a well-vaccinated population. The Pediatric infectious disease journal, 14(1), 17–22. doi.org/10.1097/00006454-199501000-00003
CDC. (2019). Vaccine Recommendations and Guidelines of the ACIP - Contraindications and Precautions. Abgerufen von https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
Chen, C. J., Lee, P. I., Hsieh, Y. C., Chen, P. Y., Ho, Y. H., Chang, C. J., . . . Lin, T. Y. (2012). Waning population immunity to measles in Taiwan. Vaccine, 30(47), 6721–6727. doi.org/10.1016/j.vaccine.2012.05.019
Chen, C. J., Lin, T. Y. & Huang, Y. C. (2018). Letter to the editor: Occurrence of modified measles during outbreak in Taiwan in 2018. Eurosurveillance, 23(37). doi.org/10.2807/1560-7917.es.2018.23.37.1800485
Cherry, J. D. (1973). Newer respiratory viruses: their role in respiratory illness of children. Advances in pediatrics, 20, 225–290. Abgerufen von pubmed.ncbi.nlm.nih.gov/4359359/
Cherry, J. D. & Zahn, M. (2018). Clinical Characteristics of Measles in Previously Vaccinated and Unvaccinated Patients in California. Clinical Infectious Diseases, 67(9), 1315–1319. doi.org/10.1093/cid/ciy286
Christenson, B. & Böttiger, M. (1994). Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine, 12(2), 129–133. doi.org/10.1016/0264-410x(94)90049-3
Clemmons, N. S., Gastanaduy, P. A., Fiebelkorn, A. P., Redd, S. B., Wallace, G. S., & Centers for Disease Control and Prevention (CDC) (2015). Measles - United States, January 4-April 2, 2015. MMWR. Morbidity and mortality weekly report, 64(14), 373–376.
CNSCBT. (2017a, Mai 19). Document elaborat de Centrul Național de Supraveghere și Control al Bolilor Transmisibile. Abgerufen am 21. Mai 2017, von http://www.cnscbt.ro/index.php/informari-saptamanale/rujeola-1/682-situatia-deceselor-datorate-rujeolei-romania-2016-2017/file
CNSCBT. (2017b, Mai 19). Situatia rujeolei in Romania la data de 19 05 2017. Abgerufen am 21. Mai 2017, von http://www.cnscbt.ro/index.php/informari-saptamanale/rujeola-1/690-situatia-rujeolei-in-romania-la-data-de-19-05-2017-1
Cohen, B., Doblas, D. & Andrews, N. (2008). Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine, 26(50), 6392–6397. https://doi.org/10.1016/j.vaccine.2008.08.074
De Serres, G., Sciberras, J., Naus, M., Boulianne, N., Duval, B. & Rochette, L. (1999). Protection after Two Doses of Measles Vaccine Is Independent of Interval between Doses. The Journal of Infectious Diseases, 180(1), 187–190. doi.org/10.1086/314847
De Serres, G., Boulianne, N., Defay, F., Brousseau, N., Benoît, M., Lacoursière, S., . . . Skowronski, D. M. (2012). Higher Risk of Measles When the First Dose of a 2-Dose Schedule of Measles Vaccine Is Given at 12–14 Months Versus 15 Months of Age. Clinical Infectious Diseases, 55(3), 394–402. https://doi.org/10.1093/cid/cis439
Dean, R. (2014). Stigmatization and Denormalization as Public Health Policies: Some Kantian Thoughts. Bioethics, 28(8), 414–419. doi.org/10.1111/bioe.12019
Defay, F., de Serres, G., Skowronski, D. M., Boulianne, N., Ouakki, M., Landry, M., . . . Ward, B. J. (2013). Measles in Children Vaccinated With 2 Doses of MMR. Pediatrics, 132(5), e1126–e1133. https://doi.org/10.1542/peds.2012-3975
Demicheli, V., Rivetti, A., Debalini, M. G. & di Pietrantonj, C. (2012). Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews, 2012(2), CD004407. https://doi.org/10.1002/14651858.cd004407.pub3
Deutscher Ethikrat. (2019, 27. Juli). Stellungnahme: Impfen als Pflicht? Abgerufen am 14. Juli 2022, von https://www.ethikrat.org/fileadmin/Publikationen/Stellungnahmen/deutsch/stellungnahme-impfen-als-pflicht.pdf
Deutschlandfunk (DLF). (2018a, Februar 24). Thomas Fischbach vs. Jan Leidel - Braucht Deutschland eine Impfpflicht für Kinderkrankheiten? Abgerufen am 9. August 2022, von www.deutschlandfunk.de/thomas-fischbach-vs-jan-leidel-braucht-deutschland-eine-100.html?dram:article_id=411412
Deutschlandfunk (DLF). (2018b, November 30). Debatte ums Impfen - „Für ein fortschrittliches Land haben wir zu viele Masern-Fälle“. Abgerufen am 9. August 2022, von www.deutschlandfunk.de/debatte-ums-impfen-fuer-ein-fortschrittliches-land-haben-100.html
Di Pietrantonj, C., Rivetti, A., Marchione, P., Debalini, M. G., & Demicheli, V. (2021). Vaccines for measles, mumps, rubella, and varicella in children. The Cochrane Database of Systematic Reviews, 11(11), CD004407. https://doi.org/10.1002/14651858.CD004407.pub5
Do, V. A., Biering-Sørensen, S., Fisker, A. B., Balé, C., Rasmussen, S. M., Christensen, L. D., Jensen, K. J., Martins, C., Aaby, P., & Benn, C. S. (2017). Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau. The Journal of infectious diseases, 215(8), 1188–1196. https://doi.org/10.1093/infdis/jiw512
European Centre for Disease Prevention and Control. (2019). Surveillance Atlas of Infectious Diseases. https://atlas.ecdc.europa.eu/public/index.aspx
European Centre for Disease Prevention and Control. (2023, April 24). Measles—Annual Epidemiological Report for 2022. https://www.ecdc.europa.eu/en/publications-data/measles-annual-epidemiological-report-2022
Eckerle, I., Keller-Stanislawski, B., Santibanez, S., Buderus, S., Hillmann, M., Drosten, C. & Eis-Hübinger, A. M. (2013). Nonfebrile Seizures after Mumps, Measles, Rubella, and Varicella-Zoster Virus Combination Vaccination with Detection of Measles Virus RNA in Serum, Throat, and Urine. Clinical and Vaccine Immunology, 20(7), 1094–1096. https://doi.org/10.1128/cvi.00084-13
Edmonson, M. B. (1990). Mild Measles and Secondary Vaccine Failure During a Sustained Outbreak in a Highly Vaccinated Population. JAMA: The Journal of the American Medical Association, 263(18), 2467. doi.org/10.1001/jama.1990.03440180073035
Edmunds, W. J. & Van Hoek, A. J. (2009). The impact of increasing vaccine coverage on the distribution of disease: measles in the UK. Centre for Infections. Abgerufen am 14. Juli 2022 von https://web.archive.org/web/20120503041132/http://www.nice.org.uk/nicemedia/live/12247/45529/45529.pdf
Ekbom, A., Daszak, P., Kraaz, W. & Wakefield, A. J. (1996). Crohn’s disease after in-utero measles virus exposure. The Lancet, 348(9026), 515–517. https://doi.org/10.1016/s0140-6736(96)04429-7
EMA. (2012). Priorix – Anhang 3: Zusammenfassung der Merkmale des Arzneimittels, Etikettierung und Packungsbeilage. Abgerufen von https://www.ema.europa.eu/en/documents/referral/priorix-article-30-referral-annex-iii_de.pdf
Engelhardt, S. J., Halsey, N. A., Eddins, D. L., & Hinman, A. R. (1980). Measles mortality in the United States 1971-1975. American journal of public health, 70(11), 1166–1169. doi.org/10.2105/ajph.70.11.1166
Faden, R. R. (1986). The History and Theory of Informed Consent. New York & Oxford, USA: Oxford University Press.
Farrington, P., Rush, M., Miller, E., Pugh, S., Colville, A., Flower, A., . . . Morgan-Capner, P. (1995). A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. The Lancet, 345(8949), 567–569. https://doi.org/10.1016/s0140-6736(95)90471-9
Fatemi Nasab, G. S., Salimi, V., Abbasi, S., Adjami Nezhad Fard, F. & Mokhtari Azad, T. (2016). Comparison of neutralizing antibody titers against outbreak-associated measles genotypes (D4, H1 and B3) in Iran. Pathogens and Disease, 74(8), ftw089. doi.org/10.1093/femspd/ftw089
Fenger, H. (2009). Ärztliche Gesundheitszeugnisse: Vorsicht ist geboten. Dtsch Arztebl 2009; 106(30): A-1506 / B-1287 / C-1255. Abgerufen von: https://www.aerzteblatt.de/archiv/65460/Aerztliche-Gesundheitszeugnisse-Vorsicht-ist-geboten
Fiebelkorn, A. P., Coleman, L. A., Belongia, E. A., Freeman, S. K., York, D., Bi, D., . . . Beeler, J. (2016). Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults. Journal of Infectious Diseases, 213(7), 1115–1123. doi.org/10.1093/infdis/jiv555
Gastañaduy, P. A., Funk, S., Lopman, B. A., Rota, P. A., Gambhir, M., Grenfell, B., & Paul, P. (2020). Factors Associated With Measles Transmission in the United States During the Postelimination Era. JAMA pediatrics, 174(1), 56–62. https://doi.org/10.1001/jamapediatrics.2019.4357
Geier, M. R. & Geier, D. A. (2003). Pediatric MMR Vaccination Safety. International Pediatrics, 18(2). Abgerufen von https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.584.5748&rep=rep1&type=pdf
Grammens, T., Schirvel, C., Leenen, S., Shodu, N., Hutse, V., Mendes Da Costa, E. & Sabbe, M. (2017). Ongoing measles outbreak in Wallonia, Belgium, December 2016 to March 2017: characteristics and challenges.Eurosurveillance, 22(17), pii=30524. https://doi.org/10.2807/1560-7917.es.2017.22.17.30524
Greenwood, K. P., Hafiz, R., Ware, R. S. & Lambert, S. B. (2016). A systematic review of human-to-human transmission of measles vaccine virus. Vaccine, 34(23), 2531–2536. https://doi.org/10.1016/j.vaccine.2016.03.092
Grgič-Vitek, M., Frelih, T., Ucakar, V., Fafangel, M., Jordan Markocic, O., Prosenc, K. & Kraigher, A. (2015). An outbreak of measles associated with an international dog show in Slovenia, November 2014. Eurosurveillance,20(3), pii=21012. https://doi.org/10.2807/1560-7917.es2015.20.3.21012
GlaxoSmithKline GmbH & Co. KG. (2003). Fachinformation Priorix®, Stand 2003. Abgerufen von: https://www.impfkritik.de/upload/pdf/fachinfo/Priorix-Glaxo-2003-01.pdf
GlaxoSmithKline GmbH & Co. KG. (Dezember, 2019). Fachinformation Priorix-Tetra ®. Abgerufen von: https://www.forum-impfen.de/images/Fachinfo/Priorix_Tetra_12_19.pdf
Greenwood, K. P., Hafiz, R., Ware, R. S., & Lambert, S. B. (2016). A systematic review of human-to-human transmission of measles vaccine virus. Vaccine, 34(23), 2531–2536. https://doi.org/10.1016/j.vaccine.2016.03.092
Haire, B., Komesaroff, P., Leontini, R., & Raina MacIntyre, C. (2018). Raising Rates of Childhood Vaccination: The Trade-off Between Coercion and Trust. Journal of bioethical inquiry, 15(2), 199–209. https://doi.org/10.1007/s11673-018-9841-1
Halsey, N. A. (1993). Increased mortality after high titer measles vaccines. The Pediatric Infectious Disease Journal, 12(6), 462–465. https://doi.org/10.1097/00006454-199306000-00002
Haralambieva, I. H., Ovsyannikova, I. G., Pankratz, V. S., Kennedy, R. B., Jacobson, R. M. & Poland, G. A. (2013). The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Review of Vaccines, 12(1), 57–70. https://doi.org/10.1586/erv.12.134
Helfand, R. F., Kim, D. K., Gary, H. E., Edwards, G. L., Bisson, G. P., Papania, M. J., . . . Anderson, L. J. (1998). Nonclassic measles infections in an immune population exposed to measles during a college bus trip. Journal of Medical Virology, 56(4), 337–341. Abgerufen von pubmed.ncbi.nlm.nih.gov/9829639/
Hussey, G. D., Goddard, E. A., Hughes, J., Ryon, J. J., Kerran, M., Carelse, E., . . . Griffin, D. E. (1996). The Effect of Edmonston-Zagreb and Schwarz Measles Vaccines on Immune Responses in Infants. Journal of Infectious Diseases, 173(6), 1320–1326. https://doi.org/10.1093/infdis/173.6.1320
Ichikawa, T., Tsuji, A., Fujino, M., Kusano, R., Sugiyama, R., Oomori, S., . . . Nakayama, T. (2013). Effect of early measles vaccination (AIK-C strain) for preterm infants. Pediatrics International, 55(2), 163–168. https://doi.org/10.1111/ped.12064
Javelle, E., Colson, P., Parola, P. & Raoult, D. (2019). Measles, the need for a paradigm shift. European Journal of Epidemiology, 34(10), 897–915. doi.org/10.1007/s10654-019-00569-4
Jefferson, T., Price, D., Demicheli, V. & Bianco, E. (2003). Unintended events following immunization with MMR: a systematic review. Vaccine, 21(25–26), 3954–3960. https://doi.org/10.1016/s0264-410x(03)00271-8
Koskiniemi, M., & Vaheri, A. (1989). Effect of measles, mumps, rubella vaccination on pattern of encephalitis in children. Lancet (London, England), 1(8628), 31–34. https://doi.org/10.1016/s0140-6736(89)91683-8
Koskiniemi, M., Korppi, M., Mustonen, K., Rantala, H., Muttilainen, M., Herrgård, E., Ukkonen, P., & Vaheri, A. (1997). Epidemiology of encephalitis in children. A prospective multicentre study. European journal of pediatrics, 156(7), 541–545. https://doi.org/10.1007/s004310050658
Kutter, S. (2015, 24. Februar). Masern-Epidemie: „Eine Masern-Impfpflicht wird nichts bringen“. Abgerufen am 9. August 2022, von www.wiwo.de/technologie/forschung/masern-epidemie-eine-masern-impfpflicht-wird-nichts-bringen/11418274.html
Kweder, H., Ainouze, M., Cosby, S. L., Muller, C. P., Lévy, C., Verhoeyen, E., . . . Buckland, R. (2014). Mutations in the H, F, or M Proteins Can Facilitate Resistance of Measles Virus to Neutralizing Human Anti-MV Sera. Advances in Virology, 2014, 1–18. https://doi.org/10.1155/2014/205617
Leuridan, E., Hens, N., Hutse, V., Ieven, M., Aerts, M. & van Damme, P. (2010). Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ, 340(may18 2), c1626. https://doi.org/10.1136/bmj.c1626
Low, N., Bavdekar, A., Jeyaseelan, L., Hirve, S., Ramanathan, K., Andrews, N. J., . . . Henao Restrepo, A. M. (2015). A Randomized, Controlled Trial of an Aerosolized Vaccine against Measles. New England Journal of Medicine, 372(16), 1519–1529. https://doi.org/10.1056/nejmoa1407417
Löll, C. (2012, 8. November). Neuerkrankungen: Masern auf dem Weg zur Erwachsenen-Krankheit. DIE WELT. Abgerufen von https://www.welt.de/gesundheit/article13679613/Masern-auf-dem-Weg-zur-Erwachsenen-Krankheit.html
Magdzik, W. & Zieliński, A. (2002). SZCZEPIENIA PRZECIW ŚWINCE - ICH SKUTECZNOŚĆ I NIEPOŻĄDANE ODCZYNY POSZCZEPIENNE. Przegląd Epidemiologiczny, 56, 377–389.
Mancuso, J. D., Krauss, M. R., Audet, S. & Beeler, J. A. (2008). ELISA underestimates measles antibody seroprevalence in US military recruits. Vaccine, 26(38), 4877–4878. https://doi.org/10.1016/j.vaccine.2008.06.028
Marinova, L., Muscat, M., Mihneva, Z. & Kojouharova, M. (2009). An update on an ongoing measles outbreak in Bulgaria, April-November 2009. Eurosurveillance, 14(50), 19442. https://doi.org/10.2807/ese.14.50.19442-en
Martins, C., Garly, M. L., Bale, C., Rodrigues, A., Benn, C. S., Whittle, H. & Aaby, P. (2013). Measles antibody levels after vaccination with Edmonston-Zagreb and Schwarz measles vaccine at 9 months or at 9 and 18 months of age: A serological study within a randomised trial of different measles vaccines. Vaccine, 31(48), 5766–5771. https://doi.org/10.1016/j.vaccine.2013.08.044
Martins, C. L., Benn, C. S., Andersen, A., Balé, C., Schaltz-Buchholzer, F., Do, V. A., . . . Garly, M. L. (2014). A Randomized Trial of a Standard Dose of Edmonston-Zagreb Measles Vaccine Given at 4.5 Months of Age: Effect on Total Hospital Admissions. The Journal of Infectious Diseases, 209(11), 1731–1738. https://doi.org/10.1093/infdis/jit804
Mathias, R. G., Meekison, W. G., Arcand, T. A. & Schechter, M. T. (1989). The role of secondary vaccine failures in measles outbreaks. American Journal of Public Health, 79(4), 475–478. doi.org/10.2105/ajph.79.4.475
Matysiak-Klose, D. (2013). Hot Spot: Epidemiologie der Masern und Röteln in Deutschland und Europa. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 56(9), 1231–1237. https://doi.org/10.1007/s00103-013-1799-x
McLean, H. Q., Fiebelkorn, A. P., Temte, J. L., Wallace, G. S., & Centers for Disease Control and Prevention (2013). Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 62(RR-04), 1–34.
MDR. (2020). EXAKT vom 18.03.2020. Abruf 19.03.2020
Merck Sharp & Dohme B.V, M.-M.-R. (2020, August). Fachinformation M-M-RVAXPRO. forum-impfen.de. https://www.forum-impfen.de/images/Fachinfo/M_M_RVAXPRO_08_20.pdf
Merck Sharp & Dohme B.V. (2022, Juli 22). Fachinformation ProQuad. fachinfo.de. https://www.fachinfo.de/pdf/021469
Mette, A., Reuss, A. M., Feig, M., Kappelmayer, L., Siedler, A., Eckmanns, T. & Poggensee, G. (2011). Under-Reporting of Measles. Deutsches Ärzteblatt international, 108(12), 191–196. https://doi.org/10.3238/arztebl.2011.0191
MHRA. (2003, 22. Mai). Statement from the Medicine and Healthcare Regulatory Agency (MHRA). Abgerufen am 14. Juli 2022, von https://webarchive.nationalarchives.gov.uk/ukgwa/20141205150130/http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con019510.pdf
Miller, C., Andrews, N., Rush, M., Munro, H., Jin, L. & Miller, E. (2004). The epidemiology of subacute sclerosing panencephalitis in England and Wales 1990–2002. Archives of Disease in Childhood, 89(12), 1145–1148. https://doi.org/10.1136/adc.2003.038489
Miller E. (2015). Controversies and challenges of vaccination: an interview with Elizabeth Miller. BMC medicine, 13, 267. https://doi.org/10.1186/s12916-015-0508-z
Millson, D. (1989). BROTHER-TO-SISTER TRANSMISSION OF MEASLES AFTER MEASLES, MUMPS, AND RUBELLA IMMUNISATION. The Lancet, 333(8632), 271. https://doi.org/10.1016/s0140-6736(89)91274-9
Mizumoto, K., Kobayashi, T. & Chowell, G. (2018). Transmission potential of modified measles during an outbreak, Japan, March‒May 2018. Eurosurveillance, 23(24). doi.org/10.2807/1560-7917.es.2018.23.24.1800239
Monafo, W., Haslam, D., Roberts, R., Zaki, S., Bellini, W. & Coffin, C. (1994). Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. The Journal of Pediatrics, 124(2), 273–276. https://doi.org/10.1016/s0022-3476(94)70318-3
Morfin, F., Beguin, A., Lina, B. & Thouvenot, D. (2002). Detection of measles vaccine in the throat of a vaccinated child. Vaccine, 20(11–12), 1541–1543. https://doi.org/10.1016/s0264-410x(01)00495-9
Moss, W. J., Griffin, D. E., & Feinstone, W. H. (2009). Measles. Vaccines for Biodefense and Emerging and Neglected Diseases, 551–565. https://doi.org/10.1016/B978-0-12-369408-9.00030-5
Mossong, J. & Muller, C. P. (2003). Modelling measles re-emergence as a result of waning of immunity in vaccinated populations. Vaccine, 21(31), 4597–4603. doi.org/10.1016/s0264-410x(03)00449-3
Mossong, J., Nokes, D. J., Edmunds, W. J., Cox, M. J., Ratnam, S. & Muller, C. P. (1999). Modeling the Impact of Subclinical Measles Transmission in Vaccinated Populations with Waning Immunity. American Journal of Epidemiology, 150(11), 1238–1249. doi.org/10.1093/oxfordjournals.aje.a009951
Muller, C. P. (2001). Measles elimination: old and new challenges? Vaccine, 19(17–19), 2258–2261. https://doi.org/10.1016/s0264-410x(00)00455-2
Murti, M., Krajden, M., Petric, M., Hiebert, J., Hemming, F., Hefford, B., . . . van Buynder, P. (2013). Case of vaccine-associated measles five weeks post-immunisation, British Columbia, Canada, October 2013. Eurosurveillance, 18(49), pii=20649. https://doi.org/10.2807/1560-7917.es2013.18.49.20649
NAVKO (2014). Bericht der Nationalen Verifizierungskommission Masern/Röteln zum Stand der Eliminierung der Masern und Röteln in Deutschland 2013. Robert Koch-Institut. Abgerufen am 14. Juli 2022, von https://web.archive.org/web/20190122224140/http://www.rki.de/DE/Content/Kommissionen/NAVKO/Berichte/Bericht_2013_de.pdf?__blob=publicationFile
Neufeind, J., Schmid-Küpke, N., Rehfuess, E., Betsch, C., & Wichmann, O. (2022). How a generally well-accepted measles vaccine mandate may lead to inequities and decreased vaccine uptake: A preregistered survey study in Germany. BMC Public Health, 22(1), 1846. https://doi.org/10.1186/s12889-022-14075-y
Olesen, A. B., Juul, S., & Thestrup-Pedersen, K. (2003). Atopic dermatitis is increased following vaccination for measles, mumps and rubella or measles infection. Acta Dermato-Venereologica, 83(6), 445–450. https://doi.org/10.1080/00015550310014997
Orenstein, W., Offit, P., Edwards, K. M. & Plotkin, S. (2017). Plotkin’s Vaccines (7. Aufl.). Philadelphia, U.S.A.: Elsevier. https://doi.org/10.1016/C2013-0-18914-3
Panum, P. L. (1939). Observations Made During the Epidemic of Measles on the Faroe Islands in the Year 1846. Journal of the American Medical Association, 115(20), 1747. doi.org/10.1001/jama.1940.02810460079037
Patel, M. K. & Orenstein, W. A. (2019). Classification of global measles cases in 2013–17 as due to policy or vaccination failure: a retrospective review of global surveillance data. The Lancet Global Health, 7(3), e313–e320. doi.org/10.1016/s2214-109x(18)30492-3
Paul Ehrlich-Institut. (2011, Juli). Bulletin zur Arzneimittelsicherheit. Abgerufen am 14. Juli 2022, von https://www.pei.de/SharedDocs/Downloads/DE/newsroom/bulletin-arzneimittelsicherheit/2011/2-2011.pdf?__blob=publicationFile&v=2
Paul-Ehrlich-Institut. (2023, Juni 20). Masern-Impfstoffe. Arzneimittel – Impfstoffe. https://www.pei.de/DE/arzneimittel/impfstoffe/masern/masern-node.html
Paunio, M., Heinonen, O. P., Virtanen, M., Leinikki, P., Patja, A., & Peltola, H. (2000). Measles history and atopic diseases: A population-based cross-sectional study. JAMA, 283(3), 343–346. https://doi.org/10.1001/jama.283.3.343
Perry, R. T. & Halsey, N. A. (2004). The Clinical Significance of Measles: A Review. The Journal of Infectious Diseases, 189(Supplement_1), S4–S16. https://doi.org/10.1086/377712
Plotkin S. A. (2010). Correlates of protection induced by vaccination. Clinical and vaccine immunology : CVI, 17(7), 1055–1065. https://doi.org/10.1128/CVI.00131-10
Poethko-Müller, C. & Mankertz, A. (2011). Sero-epidemiology of measles-specific IgG antibodies and predictive factors for low or missing titres in a German population-based cross-sectional study in children and adolescents (KiGGS). Vaccine, 29(45), 7949–7959. https://doi.org/10.1016/j.vaccine.2011.08.081
Robert Koch-Institut. (2001, 20. Juli). Epidemiologisches Bulletin Nr. 29. Abgerufen am 14. Juli 2022, von https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2001/Ausgabenlinks/29_01.pdf?__blob=publicationFile
Robert Koch-Institut. (2010, 3. September). Ratgeber für Ärzte - Masern. Abgerufen am 14. Juli 2022, von https://web.archive.org/web/20120423141137/http://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Masern.html
Robert Koch-Institut. (2012). Kontraindikationen zur Durchführung von Impfungen: Häufig gestellte Fragen und Antworten. Abgerufen von: https://www.rki.de/SharedDocs/FAQ/Impfen/AllgFr_Kontraindi/faq_impfen_Kontraindi_ges.html
Robert Koch-Institut. (2013, 1. März). Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2012. Abgerufen am 14. Juli 2022, von https://www.rki.de/DE/Content/Infekt/Jahrbuch/Jahrbuch_2012.pdf?__blob=publicationFile
Robert Koch-Institut. (2015a, Februar 9). Paramyxoviren. EM-Aufnahmen. https://www.rki.de/DE/Content/Infekt/NRZ/EM/Aufnahmen/EM-Tab_Paramyxoviren.html
Robert Koch-Institut. (2015b, 9. März). Epidemiologisches Bulletin Nr. 10. Abgerufen am 22. Juni 2015, von https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2015/Ausgaben/10_15.pdf?__blob=publicationFile
Robert Koch-Institut. (2016). Ist eine Impfung mit MMR-Impfstoff bei Hühnereiweißallergie möglich? Abgerufen von: https://www.rki.de/SharedDocs/FAQ/Impfen/MMR/FAQ10.html
Robert Koch-Institut. (2017, 1. März). Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2016. Abgerufen am 14. Juli 2022, von https://www.rki.de/DE/Content/Infekt/Jahrbuch/Jahrbuch_2016.pdf?__blob=publicationFile
Robert Koch-Institut. (2021a, 23. Juli). RKI-Ratgeber - Masern. Abgerufen am 14. Juli 2022, von https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Masern.html
Robert Koch-Institut. (2021b, November 4). Antworten auf häufig gestellte Fragen zur Schutzimpfung gegen Masern. Zielgruppe, Impfempfehlung, Impfschema. https://www.rki.de/SharedDocs/FAQ/Impfen/MMR/FAQ_Uebersicht_MSG.html
Robert Koch-Institut. (2022). Epidemiologisches Bulletin. Aktuelle Daten und Informationen zu Infektionskrankheiten und Public Health, 34/2022. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2022/Ausgaben/34_22.pdf?__blob=publicationFile
Robert Koch-Institut. (2023a, März 1). Epidemiologische Situation der Masern und Röteln in Deutschland in 2022. Eliminationsprogramme. https://www.rki.de/DE/Content/Infekt/Impfen/Praevention/elimination_04_01.html
Robert Koch-Institut. (2023b, März 14). Elimination der Masern und Röteln in Deutschland. Eliminationsprogramme. https://www.rki.de/DE/Content/Infekt/Impfen/Praevention/elimination_04.html#
Roost, H.-P., Gassner, M., Grize, L., Wüthrich, B., Sennhauser, F. H., Varonier, H. S., Zimmermann, H., & Braun-Fahrländer, C. (2004). Influence of MMR-vaccinations and diseases on atopic sensitization and allergic symptoms in Swiss schoolchildren. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 15(5), 401–407. https://doi.org/10.1111/j.1399-3038.2004.00192.x
Rota, J. S., Wang, Z. D., Rota, P. A., & Bellini, W. J. (1994). Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus research, 31(3), 317–330. https://doi.org/10.1016/0168-1702(94)90025-6
Rosen, J. B., Rota, J. S., Hickman, C. J., Sowers, S. B., Mercader, S., Rota, P. A., . . . Zimmerman, C. M. (2014). Outbreak of Measles Among Persons With Prior Evidence of Immunity, New York City, 2011. Clinical Infectious Diseases, 58(9), 1205–1210. https://doi.org/10.1093/cid/ciu105
Rowhani-Rahbar, A., Fireman, B., Lewis, E., Nordin, J., Naleway, A., Jacobsen, S. J., . . . Klein, N. P. (2013). Effect of Age on the Risk of Fever and Seizures Following Immunization With Measles-Containing Vaccines in Children. JAMA Pediatrics, 167(12), 1111. https://doi.org/10.1001/jamapediatrics.2013.2745
Rus, M., & Groselj, U. (2021). Ethics of Vaccination in Childhood-A Framework Based on the Four Principles of Biomedical Ethics. Vaccines, 9(2), 113. https://doi.org/10.3390/vaccines9020113
Salzburg Global Seminar (2011). Salzburg statement on shared decision making. BMJ (Clinical research ed.), 342, d1745. https://doi.org/10.1136/bmj.d1745
Santibanez, S., Niewiesk, S., Heider, A., Schneider-Schaulies, J., Berbers, G. A. M., Zimmermann, A., . . Hengel, H. (2005). Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? Journal of General Virology, 86(2), 365–374. doi.org/10.1099/vir.0.80467-0
Schaad, U. B. (1997). Pädiatrische Infektiologie (2. Aufl.). München, Deutschland: Mediengruppe Oberfranken.
Schönberger, K., Ludwig, M. S., Wildner, M. & Weissbrich, B. (2013). Epidemiology of Subacute Sclerosing Panencephalitis (SSPE) in Germany from 2003 to 2009: A Risk Estimation. PLoS ONE, 8(7), e68909. https://doi.org/10.1371/journal.pone.0068909
Silfverdal, S., Ehlin, A. & Montgomery, S. (2009). Breast-feeding and a subsequent diagnosis of measles. Acta Paediatrica, 98(4), 715–719. https://doi.org/10.1111/j.1651-2227.2008.01180.x
Sood, S. B., Suthar, K., Martin, K. & Mather, K. (2017). Vaccine-associated measles in an immunocompetent child. Clinical Case Reports, 5(11), 1765–1767. https://doi.org/10.1002/ccr3.1174
Sundell, N., Dotevall, L., Sansone, M., Andersson, M., Lindh, M., Wahlberg, T., . . . Andersson, L. M. (2019). Measles outbreak in Gothenburg urban area, Sweden, 2017 to 2018: low viral load in breakthrough infections. Eurosurveillance, 24(17), pii=1900114. doi.org/10.2807/1560-7917.es.2019.24.17.1900114
Taylor, L. E., Swerdfeger, A. L. & Eslick, G. D. (2014). Vaccines are not associated with autism: An evidence-based meta-analysis of case-control and cohort studies. Vaccine, 32(29), 3623–3629. https://doi.org/10.1016/j.vaccine.2014.04.085
Testing Treatments interactive. (2013, 30. Juni). Wie geht es weiter? Abgerufen am 9. August 2022, von https://de.testingtreatments.org/tt-main-text/12-wodurch-zeichnet-sich-eine-bessere-gesundheitsversorgung-aus/wie-geht-es-weiter/
Uzicanin, A. & Zimmerman, L. (2011). Field Effectiveness of Live Attenuated Measles-Containing Vaccines: A Review of Published Literature. The Journal of Infectious Diseases, 204(suppl_1), S133–S149. https://doi.org/10.1093/infdis/jir102
Weigl, J. A. I., Puppe, W., Belke, O., Neusüß, J., Bagci, F. & Schmitt, H. J. (2005). The Descriptive Epidemiology of Severe Lower Respiratory Tract Infections in Children in Kiel, Germany. Klinische Pädiatrie, 217(5), 259–267. https://doi.org/10.1055/s-2004-820352
Williamson, L. & Glaab, H. (2018). Addressing vaccine hesitancy requires an ethically consistent health strategy. BMC Medical Ethics, 19(1). doi.org/10.1186/s12910-018-0322-1
Wissenschaftlicher Dienst des Deutschen Bundestags. 2016a. Verfassungsrechtliche Zulässigkeit einer Impfpflicht. WD 3 – 3000 – 019/16. 27.01.2016.
Wissenschaftlicher Dienst des Deutschen Bundestags. 2016b. Verfassungsmäßigkeit einer gesetzlichen Impfpflicht für Kinder. WD 3 – 3000 – 056/16. 03.03.2016
World Health Organization. (2017). Weekly epidemiological record. WHO, 92, 205–228. Abgerufen von https://apps.who.int/iris/bitstream/handle/10665/255149/WER9217.pdf;jsessionid=DD14E0EA00D588E86C0EA5E8BA451C90?sequence=1
World Health Organization. (2021, 13. Juli). Measles, 1st dose (MCV1) Immunization coverage estimates by country. Abgerufen am 14. Juli 2022, von http://apps.who.int/gho/data/node.main.A826
World Health Organization. (2019). WHO UNICEF estimates of DTP3 coverage. Abgerufen von https://web.archive.org/web/20190831183659/http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragedtp3.html
Zhang, Z., Chen, M., Wang, Y., Li, J., Li, X. & Lu, L. (2019). Seroepidemiology of measles in Beijing, China: a cross-sectional study. Human Vaccines & Immunotherapeutics, 15(9), 2112–2116. doi.org/10.1080/21645515.2019.1581527
Zipprich, J., Winter, K., Hacker, J., Xia, D., Watt, J., Harriman, K., & Centers for Disease Control and Prevention (CDC) (2015). Measles outbreak--California, December 2014-February 2015. MMWR. Morbidity and mortality weekly report, 64(6), 153–154. Abgerufen am 14. Juli 2022, von https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6406a5.htm